The purpose of this study is to estimate the relative risk of severe hepatic injury in hospitalized patients with invasive candidiasis and candidemia who received anidulafungin, compared to patients who received caspofungin and/or micafungin.
Study Type
OBSERVATIONAL
Enrollment
536
This is a non-interventional study, therefore the intervention type / name do not apply
This is a non-interventional study, therefore the intervention type / name do not apply
Number of Any Severe Hepatic Injury Cases and Matched Controls
Severe hepatic injury (acute/subacute necrosis of liver, hepatic coma, hepatorenal syndrome, or hepatitis unspecified) classified as: 1) acute liver failure (associated with encephalopathy and/or coagulopathy in absence of underlying liver disease); 2) Hy's Law Criteria (serum alanine transaminase \[ALT\] levels greater than \[\>\]3 times the upper limit of normal \[ULN\] and direct bilirubin \>2 times ULN and absence of alkaline phosphatase elevation); 3) ALT levels greater than or equal to (≥) 10 times ULN; 4) ALT levels \>3 times ULN and less than (\<) 10 times ULN; or 5) classified by clinician. Disease Related Group (DRG) severity of illness coding was reported for severe hepatic injury cases and matched controls.
Time frame: 01 June 2006 to 30 June 2008 (up to 25 Months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.